The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells
Abstract
Key Points: ATRA and ATO affect NPM1 protein levels in AML cells and induce cell growth inhibition and apoptosis. AML cells with mutated NPM1 respond to ATRA/ATO, and this might be exploited therapeutically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“shifts in the balance of transcription factors related to hematopoietic differentiation have been implicated in the pathogenesis of leukemia and therapeutic agents affecting that balance are used successfully in the clinic (e.g., all-trans retinoic acid for acute myeloid leukemia). 42”
From RhoH is a negative regulator of eosinophilopoiesis (2016) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H. F., Sun, Z., Racevskis, J., Vlierberghe, P. V., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,990
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Self-citationRetinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
Mechanisms of action of arsenic trioxide.
Miller, W. H., Schipper, H. M., Lee, J. S., Singer, J. W., & Waxman, S. (2002) · PubMed · Cited by 956
Falini, B., Nicoletti, I., Martelli, M. F., & Mecucci, C. (2007) · Blood · doi:10.1182/blood-2006-07-012252 · Cited by 565
Self-citationRole of nucleophosmin in embryonic development and tumorigenesis
Grisendi, S., Bernardi, R., Rossi, M., Cheng, K., Khandker, L., Manova, K., & Pandolfi, P. P. (2005) · Nature · doi:10.1038/nature03915 · Cited by 561
PML targeting eradicates quiescent leukaemia-initiating cells
Ito, K., Bernardi, R., Morotti, A., Matsuoka, S., Saglio, G., Ikeda, Y., Rosenblatt, J., Avigan, D. E., Teruya-Feldstein, J., & Pandolfi, P. P. (2008) · Nature · doi:10.1038/nature07016 · Cited by 538
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin
Garzon, R., Garofalo, M., Martelli, M. P., Briesewitz, R., Wang, L., Fernandez-Cymering, C., Volinia, S., Liu, C., Schnittger, S., Haferlach, T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800135105 · Cited by 508
Self-citationZhu, J., Koken, M. H. M., Quignon, F., Chelbi-Alix, M. K., Degos, L., Wang, Z. Y., Chen, Z., & de Thé, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3978 · Cited by 427
PML induces a novel caspase-independent death process
Quignon, F., De Bels, F., Koken, M., Feunteun, J., Ameisen, J.-C., & de Thé, H. (1998) · Nature Genetics · doi:10.1038/3068 · Cited by 374
PML/RARA Oxidation and Arsenic Binding Initiate the Antileukemia Response of As2O3
Jeanne, M., Lallemand-Breitenbach, V., Ferhi, O., Koken, M., Le Bras, M., Duffort, S., Peres, L., Berthier, C., Soilihi, H., Raught, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.003 · Cited by 335
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
Falini, B., Martelli, M. P., Bolli, N., Sportoletti, P., Liso, A., Tiacci, E., & Haferlach, T. (2010) · Blood · doi:10.1182/blood-2010-08-299990 · Cited by 254
Self-citationOxidative stress–induced assembly of PML nuclear bodies controls sumoylation of partner proteins
Şahin, U., Ferhi, O., Jeanne, M., Benhenda, S., Berthier, C., Jollivet, F., Niwa‐Kawakita, M., Faklaris, O., Setterblad, N., de Thé, H., et al. (2014) · The Journal of Cell Biology · doi:10.1083/jcb.201305148 · Cited by 241
Acute promyelocytic leukemia, arsenic, and PML bodies
de Thé, H., Bras, M. L., & Lallemand-Breitenbach, V. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201112044 · Cited by 225
Schlenk, R. F., Dohner, K., Kneba, M., Gotze, K., Hartmann, F., del Valle, F., Kirchen, H., Koller, E., Fischer, J. T., Bullinger, L., et al. (2009) · Haematologica · doi:10.3324/haematol.13378 · Cited by 210
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia
Falini, B. (2006) · Blood · doi:10.1182/blood-2006-03-007013 · Cited by 197
Self-citationCell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin
Quentmeier, H., Martelli, M. P., Dirks, W. G., Bolli, N., Liso, A., MacLeod, R., Nicoletti, I., Mannucci, R., Pucciarini, A., Bigerna, B., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403899 · Cited by 158
Self-citationGoussetis, D. J., Gounaris, E. G., Wu, E. J., Vakana, E., Sharma, B., Bogyo, M. S., Altman, J. K., & Platanias, L. C. (2012) · Blood · doi:10.1182/blood-2012-01-402578 · Cited by 144
Balusu, R., Fiskus, W. C., Rao, R., Chong, D. G., Nalluri, S., Mudunuru, U., Ma, H., Chen, L., Venkannagari, S., Ha, K., et al. (2011) · Blood · doi:10.1182/blood-2010-09-309674 · Cited by 139
Martelli, M. P., Pettirossi, V., Thiede, C., Bonifacio, E., Mezzasoma, F., Cecchini, D., Pacini, R., Tabarrini, A., Ciurnelli, R., Gionfriddo, I., et al. (2010) · Blood · doi:10.1182/blood-2009-08-238899 · Cited by 119
Self-citationBurnett, A. K., Hills, R. K., Green, C. L., Jenkinson, S., Koo, K., Patel, Y., Guy, C., Gilkes, A., Milligan, D. W., Goldstone, A. H., et al. (2009) · Blood · doi:10.1182/blood-2009-08-236588 · Cited by 118
Flenghi, L., Fagioli, M., Tomassoni, L., Pileri, S. A., Gambacorta, M., Pacini, R., Grignani, F., Casini, T., Ferrucci, P. F., Martelli, M., et al. (1995) · Blood · doi:10.1182/blood.v85.7.1871.bloodjournal8571871 · Cited by 102
Self-citationOxidized proteins: Intracellular distribution and recognition by the proteasome
Jung, T., Bader, N., & Grune, T. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.01.030 · Cited by 78
Acute myeloid leukemia with mutated nucleophosmin (NPM1): Any hope for a targeted therapy?
Falini, B., Gionfriddo, I., Cecchetti, F., Ballanti, S., Pettirossi, V., & Martelli, M. P. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.06.001 · Cited by 76
Self-citationImpact of Genetic Features on Treatment Decisions in AML
Döhner, H., & Gaidzik, V. I. (2011) · Hematology · doi:10.1182/asheducation-2011.1.36 · Cited by 73
Impact of new prognostic markers in treatment decisions in acute myeloid leukemia
Schlenk, R. F., & Döhner, K. (2009) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283257adb · Cited by 59
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications
Sportoletti, P., Varasano, E., Rossi, R., Mupo, A., Tiacci, E., Vassiliou, G. S., Martelli, M. P., & Falini, B. (2014) · Leukemia · doi:10.1038/leu.2014.257 · Cited by 52
Self-citationRoboz, G. J., Ritchie, E. K., Curcio, T. J., Provenzano, J. L., Carlin, R. F., Samuel, M., Wittenberg, B., Mazumdar, M., Christos, P. J., Mathew, S., et al. (2008) · Cancer · doi:10.1002/cncr.23855 · Cited by 50
The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations
Tiacci, E., Rosseto, A. S., Martelli, M. P., Pasqualucci, L., Quentmeier, H., Grossmann, V., Drexler, H. G., & Falini, B. (2011) · Leukemia · doi:10.1038/leu.2011.238 · Cited by 49
Self-citationFalini, B., Martelli, M. P., Mecucci, C., Liso, A., Bolli, N., Bigerna, B., Pucciarini, A., Pileri, S. A., Meloni, G., Martelli, M. P., et al. (2008) · Haematologica · doi:10.3324/haematol.12225 · Cited by 48
Self-citationHuang, M., Thomas, D., Li, M. X., Feng, W., Chan, S. M., Majeti, R., & Mitchell, B. S. (2013) · Leukemia · doi:10.1038/leu.2013.222 · Cited by 35
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia
Martelli, M. P., Manes, N., Liso, A., Pettirossi, V., Galletti, B., Bigerna, B., Pucciarini, A., Marco, M., Pallotta, M. T., Bolli, N., et al. (2008) · Leukemia · doi:10.1038/leu.2008.149 · Cited by 28
Self-citationWang, L., Chen, B., Lin, M., Cao, Y., Chen, Y., Chen, X., Liu, T., & Hu, J. (2014) · Immunobiology · doi:10.1016/j.imbio.2014.10.015 · Cited by 27
Nazha, A., Bueso-Ramos, C., Estey, E. H., Faderl, S. H., O'Brien, S. M., Fernandez, M. H., Nguyen, M. H., Koller, C. A., Freireich, E. J., Beran, M., et al. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00218 · Cited by 23
Yi, S., Wen, L., He, J., Wang, Y., Zhao, F., Zhao, J. J., Zhao, Z., Cui, G., & Chen, Y. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2206-x · Cited by 22
Wetzler, M., Andrews, C., Ford, L. A., Tighe, S., Barcos, M. P., Sait, S. N. J., Block, A. W., Nowak, N. J., Baer, M. R., Wang, E. S., et al. (2011) · Cancer · doi:10.1002/cncr.26097 · Cited by 16
Detection of exon 12 type A mutation of NPM1 gene in IMS-M2 cell line
Thanh, H., Vũ, H. A., Iwasaki, R., Nagamura, F., Tojo, A., Watanabe, T., & Sato, Y. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.09.019 · Cited by 16
Dueling mutations in normal karyotype AML
Gallagher, R. E. (2005) · Blood · doi:10.1182/blood-2005-08-3444 · Cited by 12
Down-regulated expression of NPM1 in IMS-M2 cell line by (−)-epigallocatechin-3-gallate
Thanh, H., Lý, B. T. K., Vũ, H. A., Sato, Y., Dung, P. C., & Xinh, P. T. (2014) · Asian Pacific Journal of Tropical Biomedicine · doi:10.12980/apjtb.4.2014apjtb-2014-0177 · Cited by 10
Zheng, W., Yang, Y. A. N. G., Zhang, M., Dong, X., Tang, L., Wang, X., Zhan, Y., Yu, M., Ge, C., Ning, H., et al. (2013) · ACTA AGRONOMICA SINICA · doi:10.3724/sp.j.1206.2013.00069 · Cited by 2
Cited by
Differentiation therapy revisited
de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462
RhoH is a negative regulator of eosinophilopoiesis
Stoeckle, C., Geering, B., Yousefi, S., Rožman, S., Andina, N., Benarafa, C., & Simon, H.-U. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2016.73 · Cited by 24
Metadata
- Authors
- Martelli, M. P., Gionfriddo, I., Mezzasoma, F., Milano, F., Pierangeli, S., Mulas, F., Pacini, R., Tabarrini, A., Pettirossi, V., Rossi, R., Vetro, C., Brunetti, L., Sportoletti, P., Tiacci, E., Di Raimondo, F., & Falini, B.
- Affiliations
- Institute of Hematology, Centro di Ricerca Emato-Oncologico (CREO), University of Perugia, Perugia, Italy; and
- Institute of Hematology, University of Catania, Catania, Italy
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2015-05-28
- Volume
- 125
- Issue
- 22
- Pages
- 3455-3465
- ISSN
- 0006-4971
- 1528-0020
- Cited by
- 139
- References
- 40
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
